Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Saks Global Enterprises Seeks $1 Billion Loan Amid Possible Chapter 11 Bankruptcy Filing 
TSMC Shares Hit Record High as Goldman Sachs Raises Price Target on AI Demand Outlook 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Kia Targets 3.35 Million Global Vehicle Sales in 2026 Amid Steady Growth Outlook 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
L3Harris Nears $500M Deal to Sell Majority Stake in Space Propulsion Portfolio to AE Industrial 
Tesla Poised for Breakout Year in 2026 as New Products and EV Market Reset Drive Growth 
Samsung Electronics Hits Record High as AI Momentum Fuels Investor Optimism 
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search 
 2016 World Congress - EconoTimes)
BURLINGTON, Mass., April 01, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report results from the pivotal Phase 2b and Phase 3 clinical trials of its lead drug candidate Zilretta (also known as FX006) at the Osteoarthritis Research Society International (OARSI) 2016 World Congress at the RAI Amsterdam Convention Center in Amsterdam, The Netherlands, on Saturday, April 2 at 2:00 p.m. CET/9:00 a.m. EDT.
The presentation will be part of Concurrent Session 9 - OA Treatment - Structure and Pain with abstract presentations. The title of the scientific abstract is “Sustained and Profound Analgesic Benefits in People with Osteoarthritis of the Knee Using FX006, an Intra-articular Extended-Release Formulation of Triamcinolone Acetonide.”
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Contact Mariann Caprino TogoRun T: 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
